Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$2.12
+1.0%
$2.45
$1.83
$9.19
$28.31M1.11253,827 shs155,086 shs
Equillium, Inc. stock logo
EQ
Equillium
$1.90
+21.8%
$0.55
$0.27
$2.26
$92.82M1.1522.36 million shs13.93 million shs
Galecto, Inc. stock logo
GLTO
Galecto
$3.34
-1.2%
$3.44
$2.01
$14.82
$4.48M1.3519,563 shs3,875 shs
Imunon, Inc. stock logo
IMNN
Imunon
$6.50
-1.1%
$9.59
$4.83
$41.22
$16.04M2.16258,067 shs100,000 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
+1.94%+1.45%-19.54%-27.59%-40.68%
Equillium, Inc. stock logo
EQ
Equillium
+36.84%+59.17%+298.98%+284.24%+89.62%
Galecto, Inc. stock logo
GLTO
Galecto
-0.77%-2.36%-7.99%+10.93%-77.49%
Imunon, Inc. stock logo
IMNN
Imunon
+1.23%-0.45%-29.76%-62.24%-66.82%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
2.6053 of 5 stars
3.55.00.00.02.50.00.0
Equillium, Inc. stock logo
EQ
Equillium
0.9841 of 5 stars
1.05.00.00.02.21.70.0
Galecto, Inc. stock logo
GLTO
Galecto
3.7441 of 5 stars
3.55.00.00.03.31.71.3
Imunon, Inc. stock logo
IMNN
Imunon
1.3072 of 5 stars
3.42.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
3.00
Buy$12.00466.04% Upside
Equillium, Inc. stock logo
EQ
Equillium
2.00
Hold$1.00-47.37% Downside
Galecto, Inc. stock logo
GLTO
Galecto
3.00
Buy$10.00199.40% Upside
Imunon, Inc. stock logo
IMNN
Imunon
2.75
Moderate Buy$232.503,476.92% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$10K2,857.76N/AN/A($0.94) per share-2.26
Equillium, Inc. stock logo
EQ
Equillium
$41.10M2.75N/AN/A$0.08 per share23.75
Galecto, Inc. stock logo
GLTO
Galecto
N/AN/AN/AN/A$7.26 per shareN/A
Imunon, Inc. stock logo
IMNN
Imunon
$500K31.72N/AN/A$1.09 per share5.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$4.05M-$2.14N/AN/AN/AN/AN/A-103.70%N/A
Equillium, Inc. stock logo
EQ
Equillium
-$8.07M-$0.56N/AN/AN/A-19.62%-139.56%-90.56%N/A
Galecto, Inc. stock logo
GLTO
Galecto
-$21.44M-$13.13N/AN/AN/AN/A-115.70%-95.42%11/7/2025 (Estimated)
Imunon, Inc. stock logo
IMNN
Imunon
-$18.62M-$12.95N/AN/AN/AN/A-405.07%-158.41%11/6/2025 (Estimated)

Latest GLTO, EQ, IMNN, and DARE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$0.55-$0.45+$0.10-$0.45$0.14 million($0.02) million
8/14/2025Q2 2025
Equillium, Inc. stock logo
EQ
Equillium
-$0.14-$0.16-$0.02-$0.16N/AN/A
8/5/2025Q2 2025
Galecto, Inc. stock logo
GLTO
Galecto
N/A-$2.60N/A-$2.60N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
N/AN/AN/AN/AN/A
Equillium, Inc. stock logo
EQ
Equillium
N/AN/AN/AN/AN/A
Galecto, Inc. stock logo
GLTO
Galecto
N/AN/AN/AN/AN/A
Imunon, Inc. stock logo
IMNN
Imunon
N/AN/AN/AN/AN/A

Latest GLTO, EQ, IMNN, and DARE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2025
Imunon, Inc. stock logo
IMNN
Imunon
quarterly$0.158.57%8/7/20258/7/20258/21/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
N/A
0.34
0.56
Equillium, Inc. stock logo
EQ
Equillium
N/A
1.65
2.70
Galecto, Inc. stock logo
GLTO
Galecto
N/A
4.96
4.96
Imunon, Inc. stock logo
IMNN
Imunon
N/A
1.30
1.30

Institutional Ownership

CompanyInstitutional Ownership
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
6.70%
Equillium, Inc. stock logo
EQ
Equillium
27.05%
Galecto, Inc. stock logo
GLTO
Galecto
14.20%
Imunon, Inc. stock logo
IMNN
Imunon
4.47%

Insider Ownership

CompanyInsider Ownership
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
4.80%
Equillium, Inc. stock logo
EQ
Equillium
31.60%
Galecto, Inc. stock logo
GLTO
Galecto
10.80%
Imunon, Inc. stock logo
IMNN
Imunon
5.96%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
3013.48 million8.60 millionNot Optionable
Equillium, Inc. stock logo
EQ
Equillium
4059.50 million24.43 millionNot Optionable
Galecto, Inc. stock logo
GLTO
Galecto
401.32 million1.18 millionOptionable
Imunon, Inc. stock logo
IMNN
Imunon
302.44 million2.30 millionNot Optionable

Recent News About These Companies

Imunon (NASDAQ:IMNN) Stock Rating Upgraded by Wall Street Zen
IMNN: First Patient Dosed in Phase 3 OVATION 3 Trial…
Imunon Q2 2025 Earnings Preview
6IMNN : Insights into Imunon's Upcoming Earnings
Imunon, Inc. (IMNN) Q2 2025 Earnings Call Transcript
IMUNON Announces Reverse Stock Split

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Dare Bioscience stock logo

Dare Bioscience NASDAQ:DARE

$2.12 +0.02 (+0.95%)
Closing price 04:00 PM Eastern
Extended Trading
$2.20 +0.08 (+3.77%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Equillium stock logo

Equillium NASDAQ:EQ

$1.90 +0.34 (+21.79%)
Closing price 04:00 PM Eastern
Extended Trading
$1.97 +0.07 (+3.74%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Galecto stock logo

Galecto NASDAQ:GLTO

$3.34 -0.04 (-1.18%)
Closing price 03:50 PM Eastern
Extended Trading
$3.36 +0.02 (+0.60%)
As of 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Imunon stock logo

Imunon NASDAQ:IMNN

$6.50 -0.07 (-1.07%)
Closing price 04:00 PM Eastern
Extended Trading
$6.56 +0.06 (+0.91%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.